Precise tumor diagnosis and classification is the first step in cancer management. While many tumor biopsies are diagnostic and form the cornerstone of cancer therapy, classification of tumor type and site of origin, is an ever-present clinical challenge. It is estimated that up to 10% of all tumors have no defined primary site of origin and that thousands of dollars are spent per case to identify the site of origin with limited overall success. The current standard of pathologic practice, using morphologic criteria and a panel of semi-quantitative immunohistochemical (IHC) analyses, is often limited in its capacity to define tumor type or site of origin. Moreover, the diagnosis of metastatic lesions can be quite difficult when no primary site of origin has been identified (unknown primary cancers). Since therapy is often based on site of origin, there is a clear need for the identification and validation of a classifier that will cleanly distinguish these histologically similar tumor types and augment standard pathological techniques in making the diagnostic call. We have recently demonstrated the feasibility of using gene expression profiling to discriminate 21 different tumor types with an accuracy of 88%. The performance of this classifier, however, was principally limited by the use of multiple platforms for analysis. This proposal seeks to build a new gene expression classifier on a single, commercially available, genome-wide oligonucleotide platform, with a focus on the most problematic primary and metastatic tumors of the liver. To demonstrate the clinical utility of this approach, we plan to validate the classifier with independent test sets that will also be profiled by standard IHC approaches; the results of molecular classification will then be compared head to head with standard pathological classification for accuracy of diagnosis. To further translate the technology, we will select core classifier genes and perform validation with real time quantitative PCR. Finally, the molecular classifiers will be tested using prospectively acquired biopsy samples on tissues of known and unknown sites of origin. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA112215-03S1
Application #
7683357
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Ogunbiyi, Peter
Project Start
2006-08-10
Project End
2011-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
3
Fiscal Year
2008
Total Cost
$93,007
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Hernandez, J M; Elahi, A; Clark, C W et al. (2013) miR-675 mediates downregulation of Twist1 and Rb in AFP-secreting hepatocellular carcinoma. Ann Surg Oncol 20 Suppl 3:S625-35
Freeman, Tanner J; Smith, J Joshua; Chen, Xi et al. (2012) Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of ?-catenin. Gastroenterology 142:562-571.e2
Chen, Dung-Tsa; Hernandez, Jonathan M; Shibata, David et al. (2012) Complementary strand microRNAs mediate acquisition of metastatic potential in colonic adenocarcinoma. J Gastrointest Surg 16:905-12; discussion 912-3
Singh, Amar B; Sharma, Ashok; Smith, J Joshua et al. (2011) Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Gastroenterology 141:2140-53
Loboda, Andre; Nebozhyn, Michael V; Watters, James W et al. (2011) EMT is the dominant program in human colon cancer. BMC Med Genomics 4:9
Williams, Christopher S; Zhang, Baolin; Smith, J Joshua et al. (2011) BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. J Clin Invest 121:4056-69
Chen, Dung-Tsa; Hsu, Ying-Lin; Fulp, William J et al. (2011) Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst 103:1859-70
Chen, Dung-Tsa; Nasir, Aejaz; Venkataramu, Chinnambally et al. (2010) Evaluation of malignancy-risk gene signature in breast cancer patients. Breast Cancer Res Treat 120:25-34
Smith, J Joshua; Deane, Natasha G; Wu, Fei et al. (2010) Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 138:958-68
Krishnan, M; Singh, A B; Smith, J J et al. (2010) HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene 29:305-12

Showing the most recent 10 out of 28 publications